<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000423255"><TermName>volociximab</TermName><TermPronunciation>(voh-loh-SIK-sih-mab)</TermPronunciation><TermDefinition><DefinitionText>A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Volociximab binds to a protein that is found on cells that line some tumor blood vessels. It is a type of angiogenesis inhibitor. Also called M200.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713048" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;volociximab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713047" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;volociximab&quot;" language="es" id="_4"/><SpanishTermName>volociximab</SpanishTermName><SpanishTermDefinition><DefinitionText>Anticuerpo monoclonal en estudio para el tratamiento de algunos tipos de cáncer. Los anticuerpos monoclonales se producen en el laboratorio y pueden localizar sustancias en el cuerpo y unirse a ellas (como a las células cancerosas). Volociximab se une a una proteína que se encuentra en las células que revisten algunos vasos sanguíneos tumorales. Es un tipo de inhibidor de la angiogénesis. También se llama M200.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-05-23</DateFirstPublished><DateLastModified>2008-03-13</DateLastModified></GlossaryTerm>
